Evidence map›Paper›PMID 42824958›Full record

ArticleiScience2026

A scalable, high-throughput glue perturbation screening platform for molecular glue discovery.

Diyun Huang, Zeyu Shuang, Lu Chen, Hanyue Ouyang, Peiyu Yang, Lichang Huang, Wenchao Lu, Ming Shi, Xiaofan Ding, Baishan Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Diyun HuangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Zeyu ShuangDepartment of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Lu ChenDepartment of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Hanyue OuyangDepartment of Hepatobiliary Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Peiyu YangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Lichang HuangDepartment of Hepatobiliary Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Wenchao LuLingang Laboratory, Shanghai 200031, China.
Ming ShiDepartment of Hepatobiliary Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.
Xiaofan DingMOE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China.
Baishan JiangDepartment of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Wenchao WuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of molecular glue degraders (MGDs) is undergoing a paradigm shift from serendipitous discovery toward empirical design. However, efficiently prioritizing active leads from synthetic libraries while simultaneously confirming their E3 dependency remains a formidable challenge. In this study, we introduce the glue perturbation screening (GPS) platform, a conceptual and technical advance that integrates high-throughput, low-cost Digital RNA with pertUrbation of Genes 2 (DRUG-seq2) with isogenic cereblon (CRBN) wild-type/knockout (WT/KO) models. The significance of our work lies in the development of a multi-dimensional readout that digitizes compound activity and mechanism in a single step. By mapping transcriptomic perturbations onto a coordinate system of differential expression and gene set enrichment, we establish a tiered prioritization strategy: distinguishing high-potency glues from non-specific toxic molecules and recognizing latent biological activities in sub-threshold compounds that guide further structural optimization. This platform provides a scalable, mechanism-aware roadmap for the rational discovery of next-generation degraders, offering a powerful tool to accelerate the targeting of "undruggable" proteins.

Indexed as

CRBNdrug discoveryE3 ligasehigh-throughput screening platformmolecular glue degraderstargeted protein degradationTPD

Identifiers

PMID42824958
PMCPMC13628600

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.